MEDSynth: just a Medicinal Chemistry group
MEDSynth is a Medicinal Chemistry group funded in the late 2012 by Prof. Marco Lucio Lolli and Prof. Donatella Boschi from the Dep. Science and Drug Technology (DSTF) of the University of Torino (IT).
MEDSynth group is able to offer a complete technological platform, from the in silico design, throughout the synthesis until the in vitro / in vivo pharmacological characterization, for the design of preclinical drug candidates.
Owing around twenty years background in Medicinal and Heterocyclic chemistry, our major research interest can be found in the design of small active molecules effective in Cancer and Neglected diseases.
At the present, MEDSynth is major focused on:
- Acute Myeloid Leukemia (AML)
- Immunosuppression
- Gaba and Glutaminergic neutrasmission
- Prostate Cancer
- Neglected diseases (Malaria, Leishmania …)
Our group gives much value on young scientists' formation, investing on their advanced training.
It consists in the following flow of knowledge:
Transfer of state-of-the-art of Drug Design labs and technologies.
Involvement in high impact oncology/neglected diseases research lines.
Involvement in the international scientific network of MEDSynth.
Tutoring, mentoring and general career support.
Employment of MEDSynth graduates